Back to library
Loading…
glp1 · New England Journal of Medicine · 2023
A large clinical trial found that semaglutide significantly reduced major adverse cardiovascular events in people with overweight or obesity but without diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Escher E, Fennessy M, Gerstein HC, Guyatt G, Hansen T, Huber K, Jukema JW, Krum H, Linder M, Mach F, Mahaffey KW, McMurray JJV, Nadkarni G, Nissen SE, Noronha J, Poulter NR,
A large clinical trial found that semaglutide significantly reduced major adverse cardiovascular events in people with overweight or obesity but without diabetes.